Multiple Sclerosis

The National MS Society " supports the rights of people with MS to work with their MS health care providers to access marijuana for medical purposes in accordance with legal regulations in those states where such use has been approved."  Read full statement here:

Medical Cannabis and MS Peer Reviewed Studies

Brady, C. M., et al. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler. 2004 Aug;10(4):425-33.

Collin C. et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007 Mar. 14(3):290-6.

Consroe, P. et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol. 1997;38(1):44-8.

Corey-Bloom, Jody, et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ July 10, 2012 184:1143-1150; published ahead of print May 14, 2012, doi:10.1503/cmaj.110837.

Flachenecker P., Henze T., Zettl U. K. Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice. Eur Neurol 2014;72:95-102.

Johnson, Jeremy R. et al. Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain. Journal of Pain and Symptom Management Vol. 39, Issue 2 , 167-179.

Vaney C., et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler. 2004 Aug. 10(4):417-24.

Wade, D.T. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004 Aug. 10(4):434-41.

Whittle, B.A., Guy, G.W., Robson, P. Prospects for New Cannabis-Based Prescription Medicines. J Cannabis Ther 2001(3/4):133-152.

Zajicek, John Peter, et al. Multiple Sclerosis and Extract of Cannabis: Results of the MUSEC Trial. J Neurol Neurosurg Psychiatry 2012; 83:11 1125-1132 Published Online First: 12 July 2012 doi:10.1136/jnnp-2012-302468.



Safety and Efficacy:

GW Pharma's preliminary findings:
GW Pharma's phase I results: Porter BE1, Jacobson C.. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. 2013 Dec;29(3):574-7 Cunha et al., “Chronic Administration of Cannabidiol toHealthy Volunteers and Epileptic Patients.sup.1,” Pharmacology,21:175-185 (1980). Turkanis et al., “Electrophysiologic Properties of theCannabinoids,” J. Clin. Pharmacology.,21:449S-463S (1981). Carlini et al., “Hypnotic and Antielpileptic Effects ofCannabidiol,” J. Clin. Pharmacology.,21:417S-427S (1981). Karler et al., “The Cannabinoids as PotentialAntiepileptics,” J. Clin. Pharmacology.,21:437S-448S (1981). Consroe et al.,“Antiepileptic Potential of CannabidiolAnalgos,” J. Clin. Pharmacology.,21:428S-436S (1981). J Pharmacol Exp Ther. 1977 Apr;201(1):26-32.Cannabidiol--antiepileptic drug comparisons and interactions inexperimentally induced seizures in rats.